CAI

Caris Life Sciences, Inc.
  • Healthcare
  • Biotechnology
  • $6.88B market cap
Forecast run · Sep 14, 2026Upside rank 1063 of 3,136

Model Signal

ForecastQ Daily Probabilities
43.8%
53.0%
18.9%

Analyst Consensus

Recommendation2.14/5 Buy
Last price$24.34
Price target$26.00
Implied move+6.8%
Analysts7

ForecastQ Portfolios

CAI is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.

ForecastQ

Quantitative stocks signals powered by AI


The information provided is for educational purposes only and should not be considered financial advice. Past performance is not indicative of future results. ForecastQ is a research platform, a living documentation of an engineering experiment. We are not financial advisors.


© ForecastQ. All rights reserved.